CRH plc Advances $300 Million Share Buyback Program
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CRH plc ( (CRH)) just unveiled an announcement.
CRH plc, a leading player in the construction materials industry, announced a significant transaction involving the buyback of its ordinary shares. On July 25, 2025, CRH acquired a total of 48,938 shares across various trading venues in the United States, as part of its $300 million share buyback program announced earlier in May. This move is expected to optimize the company's capital structure and potentially enhance shareholder value by reducing the number of shares in circulation. The cancellation of these shares will result in CRH having 672,560,281 ordinary shares in issue, with an additional 38,314,040 shares held in treasury, representing 5.390% of the issued share capital.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Kimball Electronics, Inc. Announces Date For Reporting Fourth Quarter and Fiscal Year 2025 Financial Results
Kimball Electronics, Inc. (Nasdaq: KE) today announced that it will report fourth quarter and fiscal year 2025 financial results on Wednesday, August 13, 2025, after the closing of the market. The company will host a conference call and live webcast to review the results on Thursday, August 14, 2025, at 10:00 a.m. Eastern Time. The telephone number to access the conference call is 877-407-8293 / +1 201-689-8349. A live webcast of the conference call can be accessed at For those unable to participate in the live webcast, a replay will be archived at About Kimball Electronics, Inc. Kimball Electronics is a global, multifaceted manufacturer offering Electronics Manufacturing Services (EMS) and Contract Manufacturing Organization (CMO) solutions to customers around the world. From our operations in the United States, China, Mexico, Poland, Romania, and Thailand, our teams are proud to provide manufacturing services for a variety of industries. Recognized for a reputation of excellence, we are committed to a high-performance culture that values personal and organizational commitment to quality, reliability, value, speed, and ethical behavior. Kimball Electronics, Inc. (Nasdaq: KE) is headquartered in Jasper, Indiana.
Globe and Mail
3 hours ago
- Globe and Mail
European Union expects to face 15% US tariffs from Friday. But a key text still isn't ready
BRUSSELS (AP) — The European Union is working on the presumption that the United States will impose a 15% tariff on most EU exports from Friday, even though the two sides have yet to complete a key document clarifying how the agreement will operate. U.S. President Donald Trump and European Commission President Ursula von der Leyen reached a political agreement on Sunday that would see 15% duties imposed on around two-thirds of EU produce, worth around 380 billion euros ($434 billion). As of Thursday, the EU and U.S. were still working on a joint statement that would lay out the terms of their understanding, Commission spokesman Olof Gill said. The document wouldn't be legally binding. 'It is the clear understanding of the European Union that the U.S. will implement the agreed across the board tariff ceiling of 15%,' Gill said. The Commission negotiates trade terms on behalf of the the EU's 27 member countries. Carve outs were agreed for a range of 'strategic' goods, including aircraft and aircraft parts, certain chemicals, some drug generics or natural resources. Gill said that 'it is also our clear understanding that the U.S. will implement the exemptions to the 15% ceiling.' He added: 'The U.S. has made these commitments. Now it's up to the U.S. to implement them. The ball is in their court.' European wine and spirits won't escape the 15% levy on Friday, but may do later as negotiations on additional exemptions to the new tariff regime continue, he said. Chris Swonger, chief executive of the U.S. Distilled Spirits Council, said it was 'extremely disappointing' that no agreement was reached. The U.S. is the EU's biggest market for alcohol exports. 'It is critical that President Trump secure a permanent return to zero-for-zero tariffs on spirits with the European Union, which will provide much-needed certainty to 1.7 million workers who depend on a vibrant U.S. spirits industry,' Swonger said in a statement. Before last Sunday's meeting, Trump had threatened the bloc with 30% tariffs, which Von der Leyen said would effectively mean the end of trade between them. Over the last three months, the Commission drew up retaliatory measures worth tens of billions of euros to enact should the talks fail. Those countermeasures are due to take effect on Aug. 7, but Gill said they would be frozen 'if everything goes as expected.' 'If we have reached a deal, we don't need the retaliatory tariffs,' he said.
Globe and Mail
3 hours ago
- Globe and Mail
Merkel Cell Carcinoma Market is Expected to Advance at a CAGR of 8.7% Through 2034 as New Clinical Trials and Targeted Therapies Reshape Care
Merkel Cell Carcinoma Market Forecast, combines robust epidemiological data with market trends, competitive landscape analysis, and patient journey assessments. The report forecasts that the Merkel Cell Carcinoma (MCC) market in the 7MM. The Merkel Cell Carcinoma Market is expected to grow significantly in the 7MM, driven by the rising awareness among healthcare professionals contributing to earlier diagnosis, increasing chronic UV exposure, and the emergence of innovative therapies such as IFx-2.0 (TuHURA Biosciences), NIDLEGY (Philogen), MCLA 145 (Merus N.V.), ITI 3000 (Immunomic Therapeutics), PH 762 (Phio Pharmaceuticals / AgonOx), KT 253 (Kymera Therapeutics) and others. DelveInsight's latest report, ' Merkel Cell Carcinoma Market Insight, Epidemiology, and Market Forecast,' combines robust epidemiological data with market trends, competitive landscape analysis, and patient journey assessments. The report forecasts that the Merkel Cell Carcinoma (MCC) market in the 7MM which includes the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan is expected to grow at a CAGR of 8.7% from USD 411 million between 2023 to 2034 Among the 7MM, the US market represented 44% of the total market size in 2023. Other major markets, EU4 and the UK, accounted for approximately 54%. Among the EU4 and the UK, Germany held the largest Merkel Cell Carcinoma market share, followed by France. Download the report to understand which factors are driving the Merkel Cell Carcinoma therapeutic market @ Merkel Cell Carcinoma Market Trends. The report also provides an in-depth epidemiological analysis and forecasts until 2034, segmented by Total Merkel Cell Carcinoma Incident Cases, Gender-specific Incident Cases, Stage-specific Incident Cases, Etiology-specific Incident Cases of Merkel Cell Carcinoma, and Total Metastatic Merkel Cell Carcinoma Cases in the 7MM. According to DelveInsight's analysis, there were approximately 9000 incident cases of MCC in the 7MM. Among them, the United States accounted for nearly 37% of the cases in 2023. Furthermore, in the EU4 and the UK, approximately 80% of the total reported cases are associated with MCPyV, while 20% are linked to UV damage, indicating that MCPyV is the primary causative factor. Discover evolving trends in Merkel Cell Carcinoma patient pool forecasts @ Merkel Cell Carcinoma Epidemiology Analysis Recent Developments: In July 2025, the National Comprehensive Cancer Network published updated guidelines for MCC treatment with several important changes, including ctDNA monitoring, Radiation timing, Hypo-fractionated radiation, and others. In June 2025, the FDA lifted a manufacturing-related partial clinical hold on the phase 3 accelerated approval trial for immune agonist IFx-2.0. The trial evaluates IFx-2.0 as adjunctive therapy versus placebo with pembrolizumab in frontline treatment for patients with advanced or metastatic MCC. In May 2025, a new clinical trial (NCT06940440) began evaluating the innate immune agonist IFx-Hu2.0 in patients with noncutaneous MCC of unknown primary. In January 2025, 225Ac-SSO110, a somatostatin receptor 2 (SST2) antagonist for targeted radionuclide cancer treatments of MCC developed by Ariceum Therapeutics, received clearance for a Phase 1/2 trial (SANTANA-225) and is expected to begin enrolling patients in the first quarter of 2025. In April 2025, a multicenter study of 1,049 Merkel Cell Carcinoma patients found that radiation within eight weeks of diagnosis improved survival and reduced disease progression risk by 36%. Surgical margins of 1-2 cm led to better outcomes. At five years, 83% of patients were alive and 64% had no cancer progression, highlighting the importance of timely treatment and appropriate surgery. The Delveinsight report also discusses current diagnosis and treatment strategies for Merkel Cell Carcinoma. Existing drugs for MCC treatment include KEYTRUDA (Merck), ZYNYZ (Incyte Corporation/MacroGenics), and BAVENCIO (Merck KGaA). The treatment depends on the disease stage and individual factors, primarily involving surgery as the first-line therapy, often combined with radiation or chemotherapy. Chemotherapy, once a key treatment for advanced Merkel Cell Carcinoma, now plays a reduced role due to limited long-term effectiveness. Cytotoxic chemotherapy, while it has been effective for metastatic MCC, often leads to significant side effects by affecting normal cells. DelveInsight's analysis reveals that several companies are launching clinical trials to investigate new MCC treatment options or to improve existing ones. The Merkel Cell Carcinoma clinical development pipeline includes drugs such as IFx-2.0 (TuHURA Biosciences), NIDLEGY (Philogen), MCLA 145 (Merus N.V.), ITI 3000 (Immunomic Therapeutics), PH 762 (Phio Pharmaceuticals/AgonOx), and KT 253 (Kymera Therapeutics), among others. Unlock which emerging Merkel Cell Carcinoma drug is expected to capture the largest market share in 7MM by 2034. Visit the Merkel Cell Carcinoma Market Insights. Another pipeline drug, IFx-2.0 (developed by TuHURA Biosciences), is also set for phase III trial with KEYTRUDA for advanced MCC in 2025. These developments highlight the momentum in the MCC treatment landscape. MCC presents significant challenges, especially in diagnosis, due to its rarity, unclear origin, and similarity to other skin lesions. DelveInsight's leading oncology consultant commented, 'As MCCs are frequently misdiagnosed, biomarkers are needed to improve their detection to prompt biopsy to confirm diagnosis by histology and immunohistochemistry, respectively.' This highlights the potential of more precise and sensitive emerging diagnostic methods to revolutionize Merkel Cell Carcinoma treatment, driving market growth. Table of Contents 1. Key Insights 2. Report Introduction 3. Merkel Cell Carcinoma Market Overview at a Glance 4. Executive Summary 5. Key Events 6. Merkel Cell Carcinoma Background and Overview 7. Merkel Cell Carcinoma Epidemiology and Market Methodology 8. Epidemiology and Merkel Cell Carcinoma Patient Population 9. Merkel Cell Carcinoma Patient Journey 10. Merkel Cell Carcinoma Marketed Therapies 11. Merkel Cell Carcinoma Emerging Drug Profiles 12. MCC: Market Analysis 13. Key Opinion Leaders' Views 14. Merkel Cell Carcinoma Unmet Needs 15. Merkel Cell Carcinoma SWOT Analysis 16. Merkel Cell Carcinoma Market Access and Reimbursement 17. Appendix 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight Merkel Cell Carcinoma Pipeline Insight Merkel Cell Carcinoma Pipeline Insight provides comprehensive insights about the Merkel Cell Carcinoma pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Merkel Cell Carcinoma companies, including ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos therapeutics, Incyte corporation, Amgen, BioInvent International AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, Genocea Biosciences, NeoImmuneTech, and Sensei Biotherapeutics, among others. About DelveInsight DelveInsight is a leading business Healthcare consultancy and market research firm specializing in life sciences. It assists pharmaceutical companies by offering comprehensive, end-to-end solutions to improve their performance.
